Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups
Skins
  • Light
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Collapse
Brand Logo

Forum

X

xian50

@xian50
Manufacturer
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
About
Posts
2
Topics
1
Shares
0
Groups
1
Followers
1
Following
0

Posts

Recent Best Controversial

  • Disease information in Risk Management Materials
    X xian50

    @jennifer-carroll Thank you for your response. Am I correct in understanding that disease information would then likely be removed if it does not align to the part 3 of the TMA and should instead be submitted as patient information?

    PAAB Q&A

  • Disease information in Risk Management Materials
    X xian50

    Would it be possible to include basic disease information (ie what is x condition? how does it work? What are symptoms? etc) in patient-directed risk management materials? We may need to include it based on requirements from our global company's risk management program. We would anyways be submitting the piece for PAAB review/exemption however it would be good to know in advance.

    PAAB Q&A
  • Login

  • Don't have an account? Register

  • Login or register to search.
  • First post
    Last post
0
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups